What risk should justify implantable cardioverter defibrillator therapy?

Details

Serval ID
serval:BIB_520DF272047A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
What risk should justify implantable cardioverter defibrillator therapy?
Journal
American Journal of Cardiology
Author(s)
Schlapfer  J., Kappenberger  L., Fromer  M.
ISSN
0002-9149 (Print)
Publication state
Published
Issued date
03/1999
Volume
83
Number
5B
Pages
101D-103D
Notes
Journal Article
Review --- Old month value: Mar 11
Abstract
Implantable cardioverter defibrillators (ICDs) were developed to prevent sudden cardiac death in patients with ventricular tachycardia (VT) or ventricular fibrillation (VF). Their safety and efficacy have been proved in multiple retrospective and prospective studies. Many of the published trials were directed at secondary prevention for patients who had already had a sudden cardiac death or a sustained VT. For primary prevention, the information available is limited, as only 2 trials have yet been published. Ongoing trials will probably allow us to broaden the indications for prophylactic ICD implantation. Justification of the risk will have to be evaluated against complexity of the implant, the latter including not only cost but quality of life and morbidity associated with an ICD. However, our efforts still have to be directed to improve risk stratification and to decrease the complexity of the procedure.
Keywords
Death, Sudden, Cardiac/etiology/*prevention & control *Defibrillators, Implantable Humans Multicenter Studies Randomized Controlled Trials Risk Factors Survival Rate Tachycardia, Ventricular/etiology/mortality/*therapy Treatment Outcome Ventricular Fibrillation/etiology/mortality/*therapy
Pubmed
Web of science
Create date
15/02/2008 11:30
Last modification date
20/08/2019 14:07
Usage data